Document is current
Any future updates will be listed below
-
Authors
Bredon, Marius
Hausfater, Pierre
Khalki, Loubna
Tijani, Youssef
Cheikh, Amine
Brot, Loic
Creusot, Laura
Rolhion, Nathalie
Trottein, Francois
Lambeau, Gérard
Georgin-Lavialle, Sophie
Bleibtreu, Alexandre
Baudel, Jean-Luc
Lefèvre, Antoine
Emond, Patrick
Tubach, Florence
Simon-Tillaux, Noémie
Simon, Tabassome
Gorochov, Guy
Zaid, Younes
Sokol, Harry
-
Funding
Funding for this research was provided by:
Programme Hospitalier de Recherche Clinique 2020
AAP générique 2022 (ANR-23-CE15-0014-01, GUTSY, ANR-23-CE15-0014-01, GUTSY)
Balvi Filantropic Fund (PR-BLV-20220527)
DIM One Health 2020 (RPH20003DDP)
AP-HP Fondation
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 16 May 2025
First Online: 13 June 2025
Competing interests
: H.S. report lecture fee, board membership, or consultancy from Amgen, Fresenius, IPSEN, Actial, Astellas, Danone, THAC, Biose, BiomX, Eligo, Immusmol, Adare, Nestle, Ferring, MSD, Bledina, Pfizer, Biocodex, BMS, Bromatech, Gilead, Janssen, Mayoli, Roche, Sanofi, Servier, Takeda, Abbvie, has stocks from Enterome bioscience and is co-founder of Exeliom Biosciences. The other authors declare that they have no competing interests.
: The Moroccan part of the study was approved by the Local Ethics Committee of Cheikh Zaid Hospital (CEFCZ/PR/2020-PR04), Rabat, Morocco, and complies with the Declaration of Helsinki. The French part of the study was approved by a research ethics committee (CPP Ile de France XI, advice N°20026-80727) and authorized by the French agency for data security (Commission Nationale Informatique et Liberté: CNIL, authorization N°920123). The healthy subjects were recruited in the framework of the Suivitheque study (Comité de Protection des Personnes Ile-de-France IV, IRB 00003835, registration number 2012/05NICB).
